

### **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **In The Claims:**

1. (Original) A composition which, after administration to a subject, is able to induce an antibody response in that subject, wherein the antibody response is bactericidal against two or more of hypervirulent lineages A4, ET-5 and lineage 3 of *N.meningitidis* serogroup B.

2. (Original) The composition of claim 1, comprising from 2 to 10 polypeptides, each having a different amino acid sequence.

3. (Currently amended) The composition of claim 1 ~~or claim 2~~, wherein the components which give rise to the bactericidal antibody response are obtained by recombinant expression.

4. (Original) A composition comprising five meningococcal antigens: (1) a 'NadA' protein; (2) a '741' protein; (3) a '936' protein; (4) a '953' protein; and (5) a '287' protein.

5. (Original) The composition of claim 4, wherein the NadA protein has 85% or more identity to SEQ ID 2.

6. (Original) The composition of claim 5, wherein the NadA protein comprises SEQ ID 2.

7. (Currently amended) The composition of ~~any one of claims~~ claim 4 ~~to 6~~, wherein the 741 protein has 85% or more identity to SEQ ID 3.

8. (Original) The composition of claim 7, wherein the 741 protein comprises SEQ ID 3.

9. (Currently amended) The composition of ~~any one of claims~~ claim 4 ~~to 8~~, wherein the 936 protein has 85% or more identity to SEQ ID 4.

10. (Original) The composition of claim 9, wherein the 936 protein comprises SEQ ID 4.

11. (Currently amended) The composition of ~~any one of claims~~ claims 4 ~~to 10~~, wherein the 953 protein has 85% or more identity to SEQ ID 5.

12. (Original) The composition of claim 11, wherein the 953 protein comprises SEQ ID 5.

13. (Currently amended) The composition of ~~any one of claims~~ claim 4 to 12, wherein the 287 protein has 85% or more identity to SEQ ID 6.

14. (Original) The composition of claim 13, wherein the 287 protein comprises SEQ ID 6.

15. (Currently amended) The composition of ~~any one of claims~~ claim 4 to 14, wherein at least two of the antigens (1) to (5) are expressed as a single polypeptide chain.

16. (Currently amended) The composition of ~~any preceding claim~~ claim 1, wherein the composition comprises a polypeptide which comprises a pair of antigens within a single polypeptide chain selected from the group consisting of: NadA & 741; NadA & 936; NadA & 953; NadA & 287; 741 & 936; 741 & 953; 741 & 287; 936 & 953; 936 & 287; 953 & 287.

17. (Currently amended) The composition of ~~any preceding claim~~ claim 1, wherein the composition comprises a polypeptide of formula  $\text{NH}_2\text{-A-}[\text{-X-L-}]_n\text{-B-COOH}$ , wherein: X is an amino acid sequence of one of the five antigens (1) to (5); L is an optional linker amino acid sequence; A is an optional N-terminal amino acid sequence; B is an optional C-terminal amino acid sequence; and n is 2, 3, 4, or 5.

18. (Original) The composition of claim 17, wherein n is 2, X<sub>1</sub> is a 936 protein and X<sub>2</sub> is a 741 protein.

19. (Original) The composition of claim 17, wherein n is 2, X<sub>1</sub> is a 287 protein and X<sub>2</sub> is a 953 protein.

20. (Currently amended) The composition of ~~any preceding claim~~ claim 1, comprising a protein comprising SEQ ID 7.

21. (Currently amended) The composition of ~~any preceding claim~~ claim 1, comprising a protein comprising SEQ ID 8.

22. (Currently amended) The composition of ~~any preceding claim~~ claim 1, further comprising saccharide antigens from meningococcus serogroups Y, W135, C and (optionally) A.

23. (Currently amended) The composition of ~~any preceding claim~~ claim 1, further comprising a saccharide antigen from *Haemophilus influenzae* type B.

24. (Currently amended) The composition of claim 22 or claim 23, wherein the saccharide antigen is conjugated to a carrier selected from: diphtheria toxoid, ~~tetanus~~ tetanus toxoid, CRM<sub>197</sub> or *H.influenzae* protein D.

25. (Currently amended) The composition of ~~any preceding claim~~ claim 1, further comprising an antigen from *Streptococcus pneumoniae*.

26. (Currently amended) The composition of any one of claims 1 or 4 ~~preceding claim~~, for use as a medicament.

27. (Currently amended) The use of a composition of any one of claims 1 or 4 ~~preceding claim~~ in the manufacture of a medicament for the prevention and/or treatment of a disease caused by a *Neisseria*.

28. (Currently amended) A method for raising an antibody response in a mammal, comprising the step of administering an effective amount of a composition according to any one of claims 1 ~~to 26~~ or 4.

29. (Original) A polypeptide having an amino acid sequence selected from the group consisting of SEQ IDs 1 to 8.

30. (Original) A process for purifying soluble NadA from a culture medium, comprising the steps of: concentration and diafiltration against a buffer by ultrafiltration; anionic column chromatography; hydrophobic column chromatography; hydroxylapatite ceramic column chromatography; diafiltration against a buffer; and filter sterilisation.

31. (Original) A process for purifying a 936-ΔG741 hybrid protein from a bacterium, comprising the steps of homogenisation; centrifugation; cationic column chromatography; anionic column chromatography; hydrophobic column chromatography; diafiltration against a buffer; and filter sterilisation.